Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

globenewswire

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 – NEWSnet – News… as it used to be

More Press Releases

May 14, 2026

Electrovaya Reports Fiscal Year Q2 2026 Results

May 14, 2026

CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

May 14, 2026

Harte Hanks Reports First Quarter 2026 Results

May 14, 2026

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Electrovaya Reports Fiscal Year Q2 2026 Results

CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

Harte Hanks Reports First Quarter 2026 Results

GameSquare Holdings Reports 2026 First Quarter Results with Revenue up 95.0% Year-over-Year